Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as a standard therapy have been used in EGFR-mutated adenocarcinoma of non-small-cell lung cancer (NSCLC) patients in recent years. But in current randomized prospective clinical trials, due to few cases of non-adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xinyu, Wang, Zhehai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488763/
https://www.ncbi.nlm.nih.gov/pubmed/28790845
http://dx.doi.org/10.2147/OTT.S134523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488763/
https://www.ncbi.nlm.nih.gov/pubmed/28790845
http://dx.doi.org/10.2147/OTT.S134523

Ejemplares similares